SUSTAINED DELIVERY OF A MONOCLONAL ANTIBODY AGAINST SARS-COV-2 BY MICROENCAPSULATED CELLS: A PROOF-OF-CONCEPT STUDY

dc.contributor.authorAshimova, Assem
dc.contributor.authorMyngbay, Askhat
dc.contributor.authorYegorov, Sergey
dc.contributor.authorNegmetzhanov, Baurzhan
dc.contributor.authorKadyrova, Irina
dc.contributor.authorYershova, Angelina
dc.contributor.authorKart, Ulpan
dc.contributor.authorMiller, Matthew S.
dc.contributor.authorHortelano, Gonzalo
dc.date.accessioned2023-06-30T09:17:14Z
dc.date.available2023-06-30T09:17:14Z
dc.date.issued2022
dc.description.abstractBackground: Monoclonal antibody (mAb) therapy is a promising antiviral intervention for Coronovirus disease (COVID-19) with a potential for both treatment and prophylaxis. However, a major barrier to implementing mAb therapies in clinical practice is the intricate nature of mAb preparation and delivery. Therefore, here, in a pre-clinical model, we explored the possibility of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) mAb delivery using a mAb-expressing encapsulated cell system. Methods: Murine G-8 myoblasts were transfected with plasmids coding for the heavy and light chains of CR3022, a well-characterized SARS-CoV-2 mAb that targets the Spike receptor binding domain (RBD), and then encapsulated into alginate microcapsules. The microcapsules were then intraperitoneally implanted into immunocompetent (C57/BL6J) mice and changes in circulating CR3022 titres were assessed. The in vitro and ex vivo characterization of the mAb was performed using western blotting, RBD ELISA, and microscopy. Results: Transfected G-8 myoblasts expressed intact CR3022 IgG at levels comparable to transfected HEK-293 cells. Cell encapsulation yielded microcapsules harbouring approximately 1000 cells/capsule and sustainably secreting CR3022 mAb. Subsequent peritoneal G-8 microcapsule implantation into mice resulted in a gradual increase of CR3022 concentration in blood, which by day 7 peaked at 1923 [1656–2190] ng/mL and then gradually decreased ~4-fold by day 40 post-implantation. Concurrently, we detected an increase in mouse anti-CR3022 IgG titers, while microcapsules recovered by day 40 post-implantation showed a reduced per-microcapsule mAb production. Summary: We demonstrate here that cell microencapsulation is a viable approach to systemic delivery of intact SARS-CoV-2 mAb, with potential therapeutic applications that warrant further exploration.en_US
dc.identifier.citationAshimova, A. N., Myngbay, A., Yegorov, S., Negmetzhanov, B., Kadyrova, I., Yershova, A., Kart, U., Miller, M. J., & Hortelano, G. (2022). Sustained Delivery of a Monoclonal Antibody against SARS-CoV-2 by Microencapsulated Cells: A Proof-of-Concept Study. Pharmaceutics, 14(10), 2042. https://doi.org/10.3390/pharmaceutics14102042en_US
dc.identifier.urihttp://nur.nu.edu.kz/handle/123456789/7279
dc.language.isoenen_US
dc.publisherPharmaceuticsen_US
dc.rightsAttribution-NonCommercial-ShareAlike 3.0 United States*
dc.rights.urihttp://creativecommons.org/licenses/by-nc-sa/3.0/us/*
dc.subjectType of access: Open Accessen_US
dc.subjectCOVID-19en_US
dc.subjectSARS-CoV-2en_US
dc.subjectIgGen_US
dc.subjectmonoclonal antibodyen_US
dc.subjectCR3022en_US
dc.subjectcell encapsulationen_US
dc.titleSUSTAINED DELIVERY OF A MONOCLONAL ANTIBODY AGAINST SARS-COV-2 BY MICROENCAPSULATED CELLS: A PROOF-OF-CONCEPT STUDYen_US
dc.typeArticleen_US
workflow.import.sourcescience

Files

Original bundle
Now showing 1 - 1 of 1
Loading...
Thumbnail Image
Name:
pharmaceutics-14-02042-v3.pdf
Size:
1.85 MB
Format:
Adobe Portable Document Format
Description:
article
License bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
6.28 KB
Format:
Item-specific license agreed upon to submission
Description:

Collections